Global Human Papillomavirus (HPV) Vaccine Market Size and Forecast 2024-2033|Johnson & Johnson Co, Merck & Co Inc., Novartis AG, Sanofi SA, GlaxoSmithKline PLC

The Human Papillomavirus (HPV) Vaccine Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Human Papillomavirus (HPV) Vaccine Market:

https://www.thebusinessresearchcompany.com/report/human-papillomavirus-hpv-vaccine-global-market-report

According to The Business Research Company’s Human Papillomavirus (HPV) Vaccine Global Market Report 2024, The human papillomavirus (hpv) vaccine market size has grown rapidly in recent years. It will grow from $5.12 billion in 2023 to $5.87 billion in 2024 at a compound annual growth rate (CAGR) of 14.5%.  The  growth in the historic period can be attributed to initial vaccine development, medical guidelines and recommendations, government-sponsored vaccination campaigns, educational initiatives on hpv risks, improvement in vaccine accessibility.

The human papillomavirus (hpv) vaccine market size is expected to see rapid growth in the next few years. It will grow to $9.61 billion in 2028 at a compound annual growth rate (CAGR) of 13.1%.  The growth in the forecast period can be attributed to health equity and vaccine equity efforts, inclusion in travel health recommendations, targeted vaccination strategies, pharmaceutical industry investments, telemedicine and remote vaccination.. Major trends in the forecast period include innovation in adjuvant technology, role of hpv vaccination in lgbtq+ health, focus on immunocompromised populations, integration with cancer screening programs, community-based education programs.

The increased prevalence of HPV-related diseases is expected to propel the growth of the human papillomavirus (HPV) vaccine market going forward. HPV-related diseases are viral infections that frequently result in warts on the skin or mucous membranes. The HPV vaccination specifically targets the HPV subtypes. The HPV vaccine controls the risk of HPV infection and recurrent diseases. For Instance, in February 2023, according to the National Cancer Institute, a US-based Department of Health and Human Services, around 13,960 American women are anticipated to have an aggressive cervical cancer diagnosis, and 4,310 fatalities from this illness are expected in 2023 in the US. Further, 7.7 per 100,000 women per year new cases of cervical cancer were diagnosed, with an annual death rate of 2.2 per 100,000 females. Therefore, the increased prevalence of HPV-related diseases is driving the growth of the human papillomavirus (HPV) vaccine market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=12040&type=smp

The human papillomavirus (hpv) vaccine market covered in this report is segmented –

1) By Type: Tetravalent, Nonavalent, Bivalent

2) By Disease Indication: Cervical Cancer, Anal Cancer, Vulvar And Vaginal Cancer, Penile Cancer, Oropharyngeal Cancer, Other Indications

3) By Distribution Channel: Hospital And Retail Pharmacies, Government Suppliers, Other Channels

4) By Industry Vertical: Public And Private Alliance, Government Entities, Physicians, Other Industries

Product innovations are a key trend gaining popularity in the human papillomavirus (HPV) vaccine market. Companies operating in the human papillomavirus (HPV) vaccine market are adopting new technologies to sustain their position in the market. For Instance, In January 2023, the Serum Institute of India, an India-based biotechnology and biopharmaceuticals company, launched CERVAVAC, the first quadrivalent Human Papillomavirus vaccine (qHPV) created entirely by Indian scientists. The Government of India intends to immunize girls between 9 and 14 against cervical cancer, making it an affordable and cost-effective vaccine.

The human papillomavirus (hpv) vaccine market report table of contents includes:

1. Executive Summary

2. Human Papillomavirus (HPV) Vaccine Market Characteristics

3. Human Papillomavirus (HPV) Vaccine Market Trends And Strategies

4. Human Papillomavirus (HPV) Vaccine Market – Macro Economic Scenario

5. Global Human Papillomavirus (HPV) Vaccine Market Size and Growth

.

.

.

26. South America Human Papillomavirus (HPV) Vaccine Market

27. Brazil Human Papillomavirus (HPV) Vaccine Market

28. Middle East Human Papillomavirus (HPV) Vaccine Market

29. Africa Human Papillomavirus (HPV) Vaccine Market

30. Human Papillomavirus (HPV) Vaccine Market Competitive Landscape And Company Profiles

Top Major Players:

• Johnson & Johnson Co
• Merck & Co Inc
• Novartis AG
• Sanofi SA
• GlaxoSmithKline PLC

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model